

Genetic Characterization of Trimethoprim Resistance in *Haemophilus influenzae*

RONALD DE GROOT,^{1*} MARCEL SLUIJTER,¹ AD DE BRUYN,¹ JOSÉ CAMPOS,² WIL H. F. GOESSENS,³
ARNOLD L. SMITH,⁴ AND PETER W. M. HERMANS¹

Department of Pediatrics, Sophia Children's Hospital,¹ and Department of Bacteriology, University Hospital Dijkzigt,³ Erasmus University Rotterdam, Rotterdam, The Netherlands; Department of Diagnostic Microbiology, Centro Nacional de Microbiología, Instituto de Salud, Carlos III, Madrid, Spain²; and Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, Missouri⁴

Received 16 January 1996/Returned for modification 13 March 1996/Accepted 25 June 1996

We previously demonstrated that trimethoprim (Tnp) resistance in *Haemophilus influenzae* is mediated by chromosomally encoded dihydrofolate reductase (DHFR) with a modified primary structure and distinct kinetic properties. To gain insight into the relationship of the DHFR structure and the level of Tnp resistance that it confers on the host bacterium, we cloned and characterized the *folH* genes of one Tnp-susceptible and two Tnp-resistant *H. influenzae* strains. Differences were observed between Tnp-susceptible and Tnp-resistant isolates both in the promoter region and in the coding sequences. The effect of differences between *H. influenzae* *folH* genes on Tnp susceptibility was investigated in *Escherichia coli*. Various *folH* gene hybrids were constructed, and their influence on Tnp susceptibility was determined. Resistance in *E. coli* mediated by *folH* from *H. influenzae* strain R1047 was associated with alterations in the promoter and the central part of *folH*. In contrast, the *E. coli* Tnp resistance phenotype associated with the *folH* gene of *H. influenzae* R1042 was characterized by alterations in one or more of three amino acid residues at the C-terminal part of the protein. These data indicate that Tnp resistance is not only related to alterations in the promoter region of the *folH* gene and the Tnp binding domains at the N-terminal and central part of DHFR. Alterations in the C-terminal part may also cause Tnp resistance, probably as a result of a change in secondary structure and the subsequent loss of Tnp binding affinity.

Trimethoprim (Tnp), 2,4-diamino-5-(3',4',5'-trimethoxybenzyl)pyrimidine, is a synthetic compound with antibacterial and antiparasitic activities. This drug interferes with folate metabolism by inhibiting the activity of dihydrofolate reductase (DHFR) (8, 22). Tnp is often used in combination with sulfamethoxazole to treat a wide variety of aerobic gram-positive and gram-negative infections (11). Tnp-resistant microorganisms were reported shortly after the introduction of Tnp in the 1960s. Several mechanisms for Tnp resistance have been described (for a review, see reference 9). The major cause of Tnp resistance is the production of an altered (plasmid-encoded) DHFR that lacks the capacity to bind Tnp (1, 4, 23–25). Overproduction of the normal (chromosomally encoded) DHFR is an additional mechanism of resistance (3, 7, 14, 23).

We previously demonstrated that Tnp resistance in *Haemophilus influenzae* is due to chromosomally mediated overproduction of the modified DHFR (5). However, the possibility of alterations in permeability barriers or efflux pumps could not be excluded. Subsequent purification of DHFR from Tnp-susceptible and Tnp-resistant *H. influenzae* isolates indicated that the mechanism of resistance was due to a Tnp-resistant DHFR with modified structural and kinetic properties (6).

In the study described in this report we investigated the effects of differences between *H. influenzae* *folH* genes on Tnp susceptibility in *Escherichia coli*. The *folH* genes of three *H. influenzae* strains displaying different levels of susceptibility to Tnp were cloned and characterized by DNA sequencing. We

also analyzed the promoter region and the N-terminal part of the DHFRs from nine other genetically distinct *H. influenzae* isolates which varied in their Tnp susceptibilities. The effects of the various alterations in the *folH* gene on the Tnp susceptibility of the host were investigated in *E. coli* by mutagenesis experiments with *H. influenzae* *folH* gene hybrids.

MATERIALS AND METHODS

Bacterial strains and culture conditions. The *H. influenzae* isolates used in the study are listed in Table 1. These strains were grown on *Haemophilus* test medium (HTM) agar plates (Oxoid) supplemented with HTM supplement SR158 (Oxoid) and thymidine phosphorylase (Sigma, Bornem, Belgium). *E. coli* DH5 α (18), HB101 (18), and M1183 were also used in the study. Strain M1183 [*malT lda* (P_r:CI857) *malPQ endA thi hsdR*] was kindly provided by L. M. Schouls, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands. The *E. coli* strains were grown aerobically at 37°C in Luria-Bertani (LB) broth and LB agar (Difco Laboratories, Detroit, Mich.) unless stated otherwise.

Antibiotic susceptibility testing. The MIC of Tnp was determined by the agar dilution method as described previously (11a). The *E. coli* recombinants containing *H. influenzae* *folH* genes and gene hybrids (see below) were grown overnight at 37°C in LB broth containing 100 μ g of ampicillin (Sigma) per ml (18). The recombinants (10⁵ CFU in 10 μ l) were spotted onto Iso-Sensitest agar plates (Oxoid, Unipath Ltd., Basingstoke, United Kingdom) containing Tnp at graded concentrations of 0.12 to 512 μ g/ml (Sigma). The MIC was defined as the lowest concentration which completely inhibited visible growth in comparison with that on a Tnp-free agar plate. Susceptibility testing of all strains and recombinants was performed fourfold.

Cloning of the *folH* genes from various *H. influenzae* strains. The *folH* gene-containing DNA of *H. influenzae* R1047 present in recombinant pRGS7 (5, 6) was used to generate subclones in the M13 plasmids pTZ18 and pTZ19 (Sigma). Recombinant clone pRGS12 contained a 1.5-kb *EcoRI-XbaI* DNA insert. The DNA insert contained the entire *folH* gene because Tnp resistance was conferred to *E. coli* HB101 by this recombinant plasmid.

The *folH* genes from another nine Tnp-susceptible and -resistant *H. influenzae* strains from Spain were cloned. Chromosomal *H. influenzae* DNA was purified (18), and the *folH* genes were amplified by PCR. Two oligonucleotide primers (Applied Biosystems, Gouda, The Netherlands) were used for DNA amplification by PCR: 5'-GACGGATCCCAAGCCTGAATTAATTGGCTC (oligo-1;

* Corresponding author. Mailing address: Department of Pediatrics, Sophia Children's Hospital, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. Phone: 31-10-4636691. Fax: 31-10-4636449.

TABLE 1. Description of *H. influenzae* isolates

Strain	Type	Geographic origin	Isolation site	Year of isolation	Tmp MIC ($\mu\text{g/ml}$)
R906 ^a	nt ^b	NA ^c	Laboratory isolate		0.5
R1042 ^a	nt	England	Sputum	1981	128
R1047 ^a	nt	England	Eye	1981	32
1201 ^a	b	Spain	Blood	1987	32
1209 ^a	nt	Spain	Pleural fluid	1988	64
1217 ^a	nt	Spain	Blood	1988	0.25
1226	nt	Spain	Ear	1988	32
1270	nt	Spain	Ear	1989	16
1276 ^a	nt	Spain	Ear	1989	16
1288 ^a	nt	Spain	Conjunctiva	1989	64
1289 ^a	b	Spain	Pleural fluid	1989	32
1297 ^a	nt	Spain	Sputum	1989	0.12
1303 ^a	f	Spain	Cerebrospinal fluid	1989	16
1307 ^a	f	Spain	Nasopharynx	1989	8

^a *folH* genes were cloned and (partial) sequence analysis was performed.

^b nt, nontypeable.

^c NA, not applicable.

corresponding to a region upstream of the putative DHFR promoter with a *Bam*HI restriction site introduced at bases 4 to 9) and 5'-CTAGAATTCAGTTGCAGTTTTGCGTCATAAT (oligo-2; complementary to a region 3' to the termination codon with an *Eco*RI restriction site introduced at bases 4 to 9). The reaction mixtures contained 50 ng of chromosomal DNA, 50 pmol of each oligonucleotide, and 1 U of *Taq* DNA polymerase in 100 μl of PCR buffer (Perkin-Elmer Cetus, Gouda, The Netherlands). PCR amplification was performed as described previously (17). Forty cycles of PCR (2 min at 95°C, 2 min at 56°C, and 2 min at 72°C) were performed, and polymerization was continued for a further 7 min at 72°C at the end of the last cycle. PCR products were analyzed by agarose gel electrophoresis. The amplified DNA was digested with *Xba*I and *Eco*RI, cloned into pTZ18 and pTZ19, and transformed into *E. coli* HB101. The DNA cloning procedures were performed as described by Sambrook et al. (18).

DNA sequencing. Nucleotide sequence analysis of the *folH* genes of the *H. influenzae* strains was performed by the dideoxy nucleotide chain termination method (19). T7 DNA polymerase (Promega, Leiden, The Netherlands) was used in combination with the Sequenase kit of U.S. Biochemicals (Cleveland, Ohio). DNA sequencing with double-stranded plasmid templates was performed as recommended by the manufacturer. *Taq* DNA polymerase (Promega) was used to overcome band compressions. Universal M13 primers (17-mer) were used to initiate the sequence analysis. On the basis of the DNA sequence information, internal primers (20-mer) were synthesized (Applied Biosystems) to proceed with sequencing. Comparisons of different nucleotide and amino acid sequences were performed with the FastA program (13).

DHFR domain exchange experiments. The *Eco*RI-*Xba*I restriction fragments containing the *folH* genes of *H. influenzae* R1047 (*folH1*), R906 (*folH2*), and R1042 (*folH3*) were cloned into the M13 plasmid pTZ18 and plasmid pPLc245, containing the heat-inducible *p_L* promoter (15). The pTZ18 and the pPLc245 recombinant were transformed into *E. coli* DH5 α and M1183. Induction of the *p_L* promoter was performed at 42°C (18). The restriction sites *Eco*RI, *Syl*I, *Mun*I, and *Xba*I were used to construct gene hybrids by exchanging *Eco*RI-*Syl*I, *Syl*I-*Mun*I, or *Mun*I-*Xba*I *folH* gene-containing fragments. DNA cloning was carried out as described by Sambrook et al. (18). The gene hybrids were checked by restriction fragment length polymorphism analysis. For this purpose, the restriction enzymes *Alu*I, *Vsp*I, and *Mbo*I were used.

Genetic typing of the *H. influenzae* strains. To verify that the Tmp-resistant *H. influenzae* strains isolated in different geographic areas of Spain were not clonal, we characterized the strains by pulsed-field gel electrophoresis as described previously (12).

Nucleotide sequence accession numbers. The nucleotide sequences of the DHFR genes and the flanking regions of strains R1047 (*folH1*), R906 (*folH2*), and R1042 (*folH3*) are present in the EMBL, GenBank, and DDBJ databases under the accession numbers X84205, X84206, and X84207, respectively.

RESULTS

Genetic characterization of the *folH* genes from *H. influenzae* R1047, R1042, and R906. The 1.5-kb *Eco*RI-*Xba*I insert present in recombinant plasmid pRGS12 was sequenced. The first 383 nucleotides 5' of the *Eco*RI site were identical to the pGEM3 sequence. The remaining 1,144-bp sequence contained an open reading frame (Fig. 1). Within this open read-

GATCACTATCAAATAAACCTTGTGTGATCAGTTAAATAATAAAGTTGTTCCGCTTGAACAA	60
GAATAGCGACTAATGCAGATAAATGTGTCATTATCGCCAACCTTAAATTTCTGCGGGTTGCCA	120
CCGCATCATTTTCATTAATCACAGGAATAATATGTTATCTAAAAGTGCATGTAAGTAT	180
CTCGCGCATTTAAAAAACCGTTCCGCGATCTTCAATATCAGCACGAGTTAATAAAGTTGTC	240
CGATGTGAATATCATAAATAGCAAATAATTTTCCCAAGCCTGAATTAATGGCTCTGAC	300
CAACTGCTGCAAGCAGTTGCTTTGAAGCAATAGTGGTGGTAATGAGGATGATTTAAAT	360
AATGGCAGCCCGCAGCAATGGCACCAGAAGTCAAGATCACTATACGAAATCCATCATAT	420
GCAGTTGTGCAATTTGACGAAACGATTTCCATCATGTGCGGTGAATTTAGTTTGGTGAAC	480
CCTGTGTTAGTAGTACTTGTACCAAATTTCACTACGATGTTTCTTGTTCATAGTCGTTT	540
CCAAAGTTCCTAAAATGACATTAACGTTTACTATAAATCAATGACAAATCACTTAATAT	600
CAGGTATAGTAACCGCAAATTTTAGGGGGACTTATGACATTTAGTTTAAATGATAGCGAGC	660
	M T F S L I V A T
ACATTAATAAGTGTAAATGGTAAAGATAACCAAATTCCTTGGCACTTGCCTGCAGATTTA	720
T L N S V I G K D N Q I P W H L P A D L	
GCTTGGTTTCGTGAGAACCACCTGTAACCTGTCATTTGGGGCGTAAAACCTTTGAA	780
A W F R Q N T T G K P V I M G R K T F E	
AGTATGGTGTGCACTACCTAAACGTACCAATATCGTACTTCTCGCCAGCTTTTGA	840
S I G R A L P K R T N I V L S R Q L F E	
CACGAAGTGTGATGAAAGATAGCTTTGAAAGTCCGTCATTTTGTGACAGATTTT	900
H E G V I W K D S F E S A V N F V R D F	
GATGAAATATGTTGCTTGGTGGGGAGAGTTATTCAAACAATAATTTACCCAAAGCAGAT	960
D E I M L L G G G E L F K Q Y L P K A D	
AAGTTATACCTTACTCAAATCAAACGAACTAGATGGTATGATCTTTTTCCTCAATT	1020
K L Y L T Q I Q T E L D G D T F F P Q L	
AATTGGGAGGAGTGGGAAATGAAATTTGATGAATATCGTAAGGCGGATGAAACAAATCGC	1080
N W E E W E I E F D E Y R K A D E Q N R	
TATGATGCGGATTTTAAATCTTACC CGAAAATAAATCAAATAAATGAAACAAATCTTC	1140
Y D C R F L I L T R K	

TAGA 1144

FIG. 1. Nucleotide sequence of the *folH* gene of *H. influenzae* R1047. The amino acid sequence of DHFR is depicted. The -35 and -10 promoter regions are underlined.

ing frame, a protein-coding sequence started at nucleotide 634 and ended at nucleotide 1113. We designated this gene *folH1*, encoding the DHFR of *H. influenzae* R1047, for which the Tmp MIC is 32 $\mu\text{g/ml}$. The start codon is preceded by a potential ribosomal binding site (AGGG) similar to that of *E. coli* and by motifs with a high degree of homology to the canonical *E. coli* -10 (TATAAT) and -35 (TTGACA) promoters (Fig. 1) (20).

The PCR-amplified *folH* genes and flanking DNA sequences of *H. influenzae* R906 and R1042 were also analyzed by DNA sequencing. Computer analysis of the sequence revealed a DHFR-coding sequence of 480 bp. We designated the gene of Tmp-susceptible strain R906 *folH2*, while we identified that of the high-level Tmp-resistant strain R1042 (MIC, 128 $\mu\text{g/ml}$) *folH3*. Comparison of the *folH* genes of *H. influenzae* R1047, R906, and R1042 indicated that they had approximately 95% homology at the nucleotide level. The GC contents were 37.0% for *folH1* (strain R1047), 36.8% for *folH2* (strain R906), and 37.0% for *folH3* (strain R1042). The GC content of each of the three *folH* genes and flanking sequences was approximately 35%. The derived amino acid sequences of the *folH* genes were >91% identical.

Genetic relatedness of the Spanish *H. influenzae* isolates. Before examining parts of the *folH* nucleotide sequences of the Tmp-resistant Spanish isolates, we investigated the genetic heterogeneity of the strains. Only two of the strains, strains 1201 and 1289, had an identical pulsed-field pattern after digestion with *Sma*I (Fig. 2). Both of these strains were type b. The pattern seen with strain 1217 was nearly identical to that observed with the type b strains, except that the lowest-molecular-weight band was a doublet. The overall high degree of

Identification of the *folH* gene differences responsible for Tmp resistance in *H. influenzae*. The effects of the various *folH* gene alterations on the Tmp susceptibility or resistance phenotype were investigated. The MICs for three *E. coli* recombinants containing the *folH* genes of *H. influenzae* R1047 (*folH1*), R906 (*folH2*), and R1042 (*folH3*), respectively, were determined. The presence of the *folH* genes in *E. coli* invariably gave an increase in resistance to Tmp in comparison with the resistance of the wild-type strain (Fig. 5A). Furthermore, the measured MICs for the *E. coli* recombinants were significantly higher than those for the corresponding *H. influenzae* strains. This may be explained by the presence of the *folH* genes on a multicopy plasmid, causing an increase in the level of expression in *E. coli*. The association between the level of DHFR expression and the level of Tmp resistance demonstrated previously (3, 5, 7, 14, 23) was confirmed, because the presence of the heat-inducible p_L promoter influenced the level of Tmp resistance. An increase in the level of *folH2* and *folH3* gene expression by heat induction of p_L resulted in a twofold increase in the level of Tmp resistance of the recombinants. Additionally, the p_L promoter did not affect the level of expression of the *folH1* gene, presumably because of the greater distance between p_L and the structural gene (633 bp) in comparison with the distance in the homologs *folH2* and *folH3* (171 bp). Alterations in the structural *folH* genes included differences in 5 amino acid residues between strains R906 and R1047 and differences in 10 amino acid residues between strains R906 and R1042 (Fig. 6). Comparison of the three DHFR proteins demonstrated only two conserved amino acid substitutions, present in *folH2* and *folH3* at positions 74 (I \leftrightarrow V) and 79 (F \leftrightarrow L), respectively, whereas all other substitutions resulted in a change in the net protein charge (Fig. 6). In order to investigate the influence of the various alterations in the structural *folH* gene and its promoter sequence, we constructed various *folH* hybrid genes in *E. coli* and determined the MICs. The restriction enzymes *EcoRI*, *XbaI*, *StyI*, and *MunI* were applied to exchange *StyI-XbaI*, *StyI-MunI*, and *MunI-XbaI* fragments between the different *folH* genes (Fig. 6). The gene hybrids were verified by restriction fragment length polymorphism analysis. For this purpose, the restriction enzymes *AluI*, *VspI*, and *MboI* were used. *AluI* was able to discriminate the internal *StyI-MunI* fragments, and *VspI* and *MboI* sites were exclusively present in the *MunI-XbaI* fragments of *folH2* and *folH3*, respectively. Exchange of the *StyI-XbaI* fragments clearly affected the level of Tmp resistance of *folH2* and *folH3* (Fig. 5B). Since Tmp resistance was entirely transferred after *StyI-XbaI* exchange, we conclude that at least one determinant(s) involved in this type of Tmp resistance is located downstream of the *StyI* restriction site of *folH3*.

To identify the domain(s) responsible for the Tmp resistance of *folH3* strains, the *StyI-MunI* and *MunI-XbaI* fragments of *folH2* and *folH3* were exchanged. The results are presented in Fig. 5C and D. Only the alterations present in the C-terminal part of *folH3* DHFR were involved in the resistance phenotype, indicating that the three amino acid substitutions at positions 135 (E \leftrightarrow K), 142 (R \leftrightarrow H), and 154 (F \leftrightarrow V) in the DHFR of *H. influenzae* R1042 are responsible for Tmp resistance.

The Tmp resistance phenotypes of the *folH1*-containing strains were also investigated by domain substitution experiments. Transfer of the *StyI-MunI* fragments of *folH1* to *folH2* resulted in an increase in Tmp resistance (MIC, 8 to 128 μ g/ml), whereas the *folH1* recombinant containing the *StyI-MunI* domain of *folH2* showed a decrease in resistance (MIC, 512 to 64 μ g/ml) (Fig. 5C). Since the alterations present in *folH1* strains, which led to three amino acid substitutions at positions 54 (P \leftrightarrow A), 56 (A \leftrightarrow P), and 95 (I \leftrightarrow L), are all located




FIG. 5. Tmp MICs of *H. influenzae* R906, R1047, and R1042 and the various *E. coli* recombinants containing recombinant *folH* genes and hybrids constructed by DHFR domain exchange mutagenesis. All recombinant plasmids were constructed in pTZ18. The *folH1*, *folH2*, and *folH3* gene(s) and gene parts are depicted by shaded, open, and black bars, respectively. The restriction sites *EcoRI* (E), *StyI* (S), *MunI* (M), and *XbaI* (X) are depicted. Numbers in parentheses are the Tmp MICs (in micrograms per milliliter) for the *H. influenzae* strains. MIC determinations were done fourfold. The MICs were repeatedly similar. The MICs for the *E. coli* parent strains DH5 α and M1183 were <0.5 μ g/ml.

at the *StyI-MunI* part of the gene, we conclude that the central domain of DHFR encoded by *folH1* is responsible for Tmp resistance. In addition, exchange of the *StyI-MunI* fragments between *folH1* and *folH3* strains also demonstrated the presence of Tmp resistance determinants in the central domain of *folH1*. Transfer of the *StyI-MunI* fragments of *folH1* to *folH3* strains resulted in a twofold increase in Tmp resistance (MIC, 256 to 512 μ g/ml), whereas the *folH1* recombinant containing




FIG. 6. Physical map of the *EcoRI* (E)-*XbaI* (X) restriction fragments containing the *folH* genes of *H. influenzae* R906, R1047, and R1042. The amino acid differences and their positions are depicted. The black bar in the promoter region of *folH1* represents 14-bp differences in comparison with the homologous DNAs in *folH2* and *folH3*. *, *EcoRI* restriction site present in the plasmid vector pTZ18.

the *StyI*-*MunI* domain of *folH2* showed a decrease in resistance (MIC, 512 to 64 $\mu\text{g/ml}$) (Fig. 5C). Thus, exchange of the central domain of *folH1* and *folH3* clearly indicated the importance of this domain in the Tmp resistance of the *folH1* recombinant.

To investigate the involvement of the R1047 promoter in Tmp resistance, the *EcoRI*-*StyI* fragments of the *folH* genes, containing the promoter region and the 5' part of the gene, were exchanged (Fig. 5B). Substitution of the *EcoRI*-*StyI* fragment of *folH1* to *folH2* resulted in an increase in Tmp resistance (MIC, 8 to 64 $\mu\text{g/ml}$). On the other hand, substitution of the *EcoRI*-*StyI* fragment of *folH1* by *folH2* resulted in a decrease in Tmp resistance (MIC, 512 to 128 $\mu\text{g/ml}$). Since two amino acid substitutions are present at positions 13 (N \leftrightarrow S) and 21 (M \leftrightarrow I), we conclude that the promoter or the substitutions at positions 13 and 21, or both the promoter and the substitutions are involved in the Tmp resistance of the *folH1* recombinant.

DISCUSSION

In the present study, the *folH* genes and flanking sequences of three *H. influenzae* strains that vary in their levels of Tmp resistance were characterized. The base compositions of the *folH2* gene of the Tmp-susceptible strain R906 and the *folH1* and *folH3* genes of Tmp-resistant strains R1047 and R1042, respectively, were similar to that of the *H. influenzae* chromosome: G+C contents of 37.0% (*folH1*), 36.8% (*folH2*), and 37.0% (*folH3*), in comparison with 39% for the entire chromosome (10). This observation suggests that Tmp resistance in *H. influenzae* is due to alterations that occur in the species-specific *folH* genes rather than the horizontal transfer of resistance genes from other bacterial species.

Comparison of the translated products of the three *folH* genes revealed more than 95% sequence identity. Computer analysis of the deduced DHFR amino acid sequences demonstrated significant homology with other prokaryotic and eukaryotic DHFRs. The DHFR protein of *H. influenzae* R1047 encoded by *folH1* had 48% identity and 51.3% similarity in an overlap of 158 amino acids with the DHFR of *E. coli* K-12 (21).

The homologies of the deduced protein with other prokaryotic Tmp-resistant and -susceptible DHFRs varied between 34.9 and 49.1%. Homology with eukaryotic DHFRs was significantly less and was mainly restricted to the first 68 amino acids.

Since overproduction of the wild-type DHFR is a mechanism of Tmp resistance in *E. coli*, which is associated with mutations in the promoter region, the 52-bp nucleotide sequence upstream of the putative *folH* start codon was determined in various *H. influenzae* strains. Since this region in the Tmp-resistant strain R1042, which appeared to overproduce a modified DHFR by sixfold compared with the level of production by Tmp-susceptible strain R906 (6), was identical to the *folH* promoter region of strain R906, we conclude that overproduction of DHFR is presumably caused by unknown regulatory mechanisms affecting the expression of DHFR.

The DHFR production of *H. influenzae* R1047 was demonstrated to be 11.5 times greater than that of strain R906 (6). We observed two nucleotide differences among the *folH* promoter regions of these strains. Furthermore, the R1047 *folH* promoter sequence was identical to the homologous sequences in four Spanish isolates that were invariably resistant to Tmp. These data suggest that the promoter sequence of R1047 may be (partly) responsible for DHFR overproduction and the subsequent Tmp resistance phenotype of the strain.

The effects of the various *H. influenzae* *folH* gene alterations on the Tmp susceptibility or resistance phenotype were investigated in *E. coli*. Various *folH* gene hybrids were constructed, and the influence on Tmp susceptibility was determined. We demonstrated that one or more of three amino acid substitutions in the C-terminal part of *folH3* (strain R1042; MIC, 128 $\mu\text{g/ml}$) were associated with the expression of Tmp resistance in *E. coli*. The Tmp resistance of *folH1* (strain R1047; MIC, 32 $\mu\text{g/ml}$) was associated with amino acid substitutions in the central part of DHFR. In addition, promoter activity or amino acid substitutions in the N-terminal part of *folH1*, or both, were also involved in Tmp resistance. Interestingly, the binding domains of inhibitory components such as Tmp are present at the N-terminal and central parts of the protein (2). The C-terminal part of DHFR has never been shown to harbor binding do-

mains. A possible explanation for the importance of alterations in the C-terminal part of DHFR may be the contributory effects of this region on the maintenance of the secondary structure of the enzyme. Alterations in this region may lead to a change in structure, which causes a loss of or a decrease in the level of Tmp binding and subsequently results in a Tmp resistance phenotype.

ACKNOWLEDGMENTS

We are indebted to Pilar Aparicio and Federico Román for support with pulsed-field gel electrophoresis.

This work was supported by the Sophia Foundation for Scientific Research, Rotterdam, The Netherlands (to R.D.G.), and by the Ministerio de Educación y Ciencia, Madrid, Spain (PM91-0179-C03-01) (to J.C.).

REFERENCES

1. Amyes, S. G. B., K. J. Towner, G. I. Carter, C. J. Thomson, and H. K. Young. 1989. The type VII dihydrofolate reductase: a novel plasmid-encoded trimethoprim-resistant enzyme from gram-negative bacteria isolated in Britain. *J. Antimicrob. Chemother.* **24**:111-119.
2. Barclay, B. J., T. Huang, M. G. Nagel, V. L. Misener, J. C. Game, and G. M. Wahl. 1988. Mapping and sequencing of the dihydrofolate reductase gene (DFR1) of *Saccharomyces cerevisiae*. *Gene* **63**:175-185.
3. Burchall, J. J., L. P. Elwell, and M. E. Fling. 1982. Molecular mechanisms of resistance to trimethoprim. *Rev. Infect. Dis.* **4**:246-254.
4. Burns, J. L., D. M. Lien, and L. A. Hedin. 1989. Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant *Pseudomonas cepacia*. *Antimicrob. Agents Chemother.* **33**:1247-1251.
5. De Groot, R., J. Campos, S. L. Moseley, and A. L. Smith. 1988. Molecular cloning and mechanism of trimethoprim resistance in *Haemophilus influenzae*. *Antimicrob. Agents Chemother.* **32**:477-484.
6. De Groot, R., D. O. Chaffin, M. Kuehn, and A. L. Smith. 1991. Trimethoprim resistance in *Haemophilus influenzae* is due to altered dihydrofolate reductase(s). *Biochem. J.* **274**:657-662.
7. Flensburg, J., and O. Sköld. 1987. Massive overproduction of dihydrofolate reductase as a response to the use of trimethoprim. *Eur. J. Biochem.* **162**:473-476.
8. Hitchings, G. H., and J. J. Burchall. 1965. Inhibition of folate biosynthesis and function as a basis for chemotherapy. *Adv. Enzymol.* **27**:417-468.
9. Huovinen, P., L. Sundström, G. Swedberg, and O. Sköld. 1995. Trimethoprim and sulfonamide resistance. *Antimicrob. Agents Chemother.* **39**:279-289.
10. Kauc, L., M. Mitchell, and S. H. Goodgal. 1989. Size and physical map of the chromosome of *Haemophilus influenzae*. *J. Bacteriol.* **171**:2474-2479.
11. Kucers, A., and N. Bennett. 1987. Trimethoprim, co-trimoxazole (Co-T), and other trimethoprim combinations, p. 1118-1202. *In* A. Kucers and N. Bennett (ed.), *The use of antibiotics*. William Heinemann Medical Books, London.
- 11a. Lennette, E. H., A. Balows, W. J. Hausler, Jr., and H. J. Shadomy (ed.). 1985. *Manual of clinical microbiology*, 4th ed. American Society for Microbiology, Washington, D.C.
12. Lou, E., B. W. Birren, S. M. Clark, M. I. Simon, and L. Hood. 1989. Pulsed-field gel electrophoresis. *BioTechniques* **7**:34-42.
13. Pearson, W. R., and D. J. Lipman. 1988. Improved tools for biological sequence comparison. *Proc. Natl. Acad. Sci. USA* **85**:2444-2448.
14. Powell, M., Y. Hu, and D. M. Livermore. 1991. Resistance to trimethoprim in *Haemophilus influenzae*. *Infection* **19**:174-177.
15. Remaut, E., P. Stanssens, and W. Fiers. 1983. Inducible high level synthesis of mature fibroblast interferon in *Escherichia coli*. *Nucleic Acids Res.* **11**:4677-4688.
16. Rouch, D. A., L. J. Messerotti, L. S. L. Loo, C. A. Jackson, and R. A. Skurray. 1989. Trimethoprim resistance transposon Tn4003 from *Staphylococcus aureus* encodes genes for a dihydrofolate reductase and thymidylate synthetase flanked by three copies of IS257. *Mol. Microbiol.* **3**:161-175.
17. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, and H. A. Erlich. 1988. Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* **239**:487-491.
18. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
19. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**:5463-5467.
20. Shine, J., and L. Dalgarno. 1974. The 3'-terminal sequence of *Escherichia coli* 16S ribosomal RNA: complementarity to nonsense triplets and ribosome binding site. *Proc. Natl. Acad. Sci. USA* **71**:1342-1346.
21. Smith, D. R., and J. M. Calvo. 1980. Nucleotide sequence of the *E. coli* gene encoding for dihydrofolate reductase. *Nucleic Acids Res.* **8**:2255-2274.
22. Smith, J. T., and S. G. B. Amyes. 1984. Bacterial resistance to antifolate chemotherapeutic agents mediated by plasmids. *Br. Med. Bull.* **40**:42-46.
23. Then, R. L. 1982. Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulphamethoxazole. *Rev. Infect. Dis.* **4**:261-269.
24. Wylie, B. A., S. G. B. Amyes, H. K. Young, and H. J. Koornof. 1988. Identification of a novel plasmid-encoded dihydrofolate reductase mediating high level resistance to trimethoprim. *J. Antimicrob. Chemother.* **22**:429-435.
25. Young, H. K., and S. G. B. Amyes. 1986. A new mechanism of plasmid trimethoprim resistance. *J. Biol. Chem.* **261**:2503-2505.